Autoimmune Hepatitis

Immunology
5
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

S
SteroTherapeuticsPA - Doylestown
1 program
1
CannabidiolPhase 21 trial
Active Trials
NCT04129489TerminatedEst. Mar 2020
Veloxis Pharmaceuticals
1 program
1
LCP-TacroPhase 21 trial
Active Trials
NCT00608894TerminatedEst. Jul 2009
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
RO7049665Phase 21 trial
Active Trials
NCT04790916Terminated2Est. Nov 2021
KL
Kezar Life SciencesCA - South SF
1 program
1
zetomipzomibPhase 21 trial
Active Trials
NCT05569759CompletedEst. Apr 2025
Stuart Therapeutics
1 program
1
Orencia®Phase 11 trial
Active Trials
NCT04203875TerminatedEst. Jul 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Kezar Life Scienceszetomipzomib
RocheRO7049665
SteroTherapeuticsCannabidiol
Veloxis PharmaceuticalsLCP-Tacro
Stuart TherapeuticsOrencia®

Clinical Trials (5)

Total enrollment: 2 patients across 5 trials

NCT05569759Kezar Life Scienceszetomipzomib

A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Start: May 2023Est. completion: Apr 2025
Phase 2Completed
NCT04790916RocheRO7049665

Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

Start: Apr 2021Est. completion: Nov 20212 patients
Phase 2Terminated
NCT04129489SteroTherapeuticsCannabidiol

A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

Start: Feb 2019Est. completion: Mar 2020
Phase 2Terminated
NCT00608894Veloxis PharmaceuticalsLCP-Tacro

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Start: Dec 2007Est. completion: Jul 2009
Phase 2Terminated
NCT04203875Stuart TherapeuticsOrencia®

Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

Start: Mar 2020Est. completion: Jul 2020
Phase 1Terminated

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
13h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
14h ago

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Johnson & Johnson
Seattle, Washington, United States of America
Yesterday
$100K - $175K/yr

Senior Medical Science Liaison, Dermatology - Indianapolis

Johnson & Johnson
Indianapolis, Indiana, United States
Yesterday
$137K - $236K/yr

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
Yesterday

Supply Chain and Procurement Controller

Ferring Pharmaceuticals
Hvidovre, Denmark
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)